Transcend Therapeutics
Biotechnology ResearchView the employees at
Transcend Therapeutics-
Sarah Olmstead, PhD R&D Manager at Transcend Therapeutics
-
Philadelphia, Pennsylvania, United States
-
Top 10%
Alyssa McNamara Clinical Trial Manager at Transcend Therapeutics-
Santa Cruz, California, United States
-
Rising Star
Stephanie Galinos Sr. Clinical Trial Associate at Transcend Therapeutics-
New York, New York, United States
-
Rising Star
Megan Kelly Chief of Staff at Transcend Therapeutics-
New York, New York, United States
-
Rising Star
Amanda Jones Sr. Vice President, Clinical Development-
San Francisco Bay Area
-
Rising Star
Overview
Transcend Therapeutics is a clinical-stage, neuroscience-focused company developing next-generation psychoactive medicines for neuropsychiatric disease. Transcend develops medicines that are accessible to a larger percentage of patients in need, specifically the tens of millions of patients who already take psychotropic medication. We have real-world data showing that our lead product provided significant benefit to >85% of patients with PTSD and depression. We have already advanced our lead compound into an approved Phase II study in PTSD, with plans to expand into depression and other indications. Transcend’s leadership team includes the first scientist to receive federal funding for clinical psychedelic research in over 50 years and drug development executives with pivotal contributions to 13 FDA approvals, including the most recently approved drug for depression, and $7B dollars in M&A and public company value. Transcend has raised approximately $42M to date, and has been featured in the Wall Street Journal, Forbes, and Politico. As a Public Benefit Corporation, we have pledged 10% of founding shares toward nonprofits focused on scientific research and patient access.
-